Insmed (INSM) Total Current Liabilities (2010 - 2026)
Insmed (INSM) recorded quarterly Total Current Liabilities of $361.0 million in Q1 2026, down 23.01% quarter-over-quarter from $468.9 million in Q4 2025, and up 50.9% on a YoY basis from $239.2 million in Q1 2025.
Insmed (INSM) Total Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $361.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 50.9% year-over-year to $361.0 million; the TTM figure through Mar 2026 stood at $361.0 million (up 50.9% YoY), while the FY2025 annual figure was $468.9 million, up 57.59% from the prior year.
- Total Current Liabilities was $361.0 million for Q1 2026 at Insmed, down from $468.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $524.2 million in Q2 2024 to a low of $113.8 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $275.4 million across 5 years, with a median of $239.2 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 156.61% in 2024, then tumbled 43.16% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $190.2 million in 2022, then climbed by 18.6% to $225.6 million in 2023, then jumped by 31.87% to $297.5 million in 2024, then soared by 57.59% to $468.9 million in 2025, then slipped by 23.01% to $361.0 million in 2026.
- The last three Total Current Liabilities figures came in at $361.0 million (Q1 2026), $468.9 million (Q4 2025), and $417.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 72.86 Mn |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 361.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361.01 Mn |
| Dec 31, 2025 | 468.87 Mn |
| Sep 30, 2025 | 417.21 Mn |
| Jun 30, 2025 | 311.68 Mn |
| Mar 31, 2025 | 239.23 Mn |
| Dec 31, 2024 | 297.53 Mn |
| Sep 30, 2024 | 259.19 Mn |
| Jun 30, 2024 | 524.15 Mn |
| Mar 31, 2024 | 420.86 Mn |
| Dec 31, 2023 | 225.63 Mn |
| Sep 30, 2023 | 196.73 Mn |
| Jun 30, 2023 | 204.26 Mn |
| Mar 31, 2023 | 187.98 Mn |
| Dec 31, 2022 | 190.24 Mn |
| Sep 30, 2022 | 137.65 Mn |
| Jun 30, 2022 | 113.82 Mn |
| Mar 31, 2022 | 125.25 Mn |
| Dec 31, 2021 | 135.17 Mn |
| Sep 30, 2021 | 112.50 Mn |
| Jun 30, 2021 | 99.66 Mn |